Literature DB >> 1851580

Vanishing bile-duct syndrome following liver transplantation--is it reversible?

S G Hubscher1, J A Buckels, E Elias, P McMaster, J Neuberger.   

Abstract

Loss of bile ducts is a characteristic feature of chronic rejection in the liver allograft (also known as irreversible rejection and vanishing bile-duct syndrome). Typically, this occurs as a progressive lesion resulting in irreversible damage and graft failure requiring retransplantation. In this study, we describe 6 patients who developed a transient loss of bile ducts following liver transplantation. This occurred in a series of 138 patients who underwent the first 160 liver transplant operations in the Birmingham Liver Transplant Programme (incidence = 4.4% of patients, 3.7% of grafts). Forty needle biopsies were obtained from the 6 patients between 6 and 1303 days after transplantation. Thirteen specimens, taken between 8 and 1253 days posttransplant (median 98 days) showed an absence of bile ducts in more than 50% of portal tracts. Other histologic features of chronic rejection, inflammatory bile-duct lesions, perivenular cholestasis, and hepatocyte dropout were also seen in these biopsies, and severe cholestasis was present biochemically (median serum bilirubin level 240 mumol/L). The histologic and biochemical changes were thought to be compatible with a diagnosis of chronic/irreversible rejection, but the decision to carry out retransplantation was deferred on the basis of stable and, subsequently, improving biochemistry. Follow-up biopsies showed recovery of duct loss and other histologic abnormalities. All 6 patients are currently alive and well with good graft function. It is concluded that a transient, reversible bile-duct loss can occur after liver transplantation and that cases with this condition are indistinguishable from those who subsequently develop irreversible graft damage. In view of the risks associated with additional immunosuppression and/or retransplantation, caution is advocated in the interpretation of ductopenia in posttransplant liver biopsies. We suggest that the term "early chronic rejection" might be appropriate to describe cases in which a definite diagnosis of irreversible graft damage cannot be made.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851580     DOI: 10.1097/00007890-199105000-00014

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  16 in total

Review 1.  [Current aspects of liver allograft pathology].

Authors:  U Drebber; M Torbenson; I Wedemeyer; H P Dienes
Journal:  Pathologe       Date:  2011-03       Impact factor: 1.011

Review 2.  Liver transplantation in the UK.

Authors:  S R Bramhall; E Minford; B Gunson; J A Buckels
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 3.  Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts.

Authors:  A J Demetris; N Murase; R G Lee; P Randhawa; A Zeevi; S Pham; R Duquesnoy; J J Fung; T E Starzl
Journal:  Ann Transplant       Date:  1997       Impact factor: 1.530

4.  Pathology of Chronic Rejection: An Overview of Common Findings and Observations About Pathogenic Mechanisms and Possible Prevention.

Authors:  A J Demetris; N Murase; T E Starzl; J J Fung
Journal:  Graft (Georget Tex)       Date:  1998-05

Review 5.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

6.  Risk factors for liver rejection: evidence to suggest enhanced allograft tolerance in infancy.

Authors:  M S Murphy; R Harrison; P Davies; J A Buckels; A D Mayer; S Hubscher; D A Kelly
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

7.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

8.  Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.

Authors:  A Jain; A J Demetris; R Kashyap; K Blakomer; K Ruppert; A Khan; S Rohal; T E Starzl; J J Fung
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

Review 9.  Aspects of liver transplant pathology with emphasis on rejection and its mechanisms.

Authors:  D G Wight
Journal:  J Clin Pathol       Date:  1994-04       Impact factor: 3.411

10.  Mycophenolate mofetil for drug-induced vanishing bile duct syndrome.

Authors:  S-Simona Jakab; A-Brian West; Dennis-M Meighan; Robert S Brown; William-B Hale
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.